Aarti Pharmalabs Limited (AARTIPHARM.BO)
- Previous Close
798.65 - Open
797.00 - Bid 780.10 x --
- Ask 781.50 x --
- Day's Range
778.85 - 809.50 - 52 Week Range
495.60 - 837.00 - Volume
27,678 - Avg. Volume
39,278 - Market Cap (intraday)
70.709B - Beta (5Y Monthly) -0.65
- PE Ratio (TTM)
25.98 - EPS (TTM)
30.03 - Earnings Date Aug 5, 2025 - Aug 6, 2025
- Forward Dividend & Yield 3.50 (0.46%)
- Ex-Dividend Date Feb 14, 2025
- 1y Target Est
--
Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acidic and allied products comprising sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India.
www.aartipharmalabs.com2,095
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AARTIPHARM.BO
View MorePerformance Overview: AARTIPHARM.BO
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AARTIPHARM.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AARTIPHARM.BO
View MoreValuation Measures
Market Cap
72.39B
Enterprise Value
75.90B
Trailing P/E
26.59
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.42
Price/Book (mrq)
3.64
Enterprise Value/Revenue
3.59
Enterprise Value/EBITDA
16.00
Financial Highlights
Profitability and Income Statement
Profit Margin
12.12%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
20.57B
Net Income Avi to Common (ttm)
2.49B
Diluted EPS (ttm)
30.03
Balance Sheet and Cash Flow
Total Cash (mrq)
995.13M
Total Debt/Equity (mrq)
20.81%
Levered Free Cash Flow (ttm)
--